Genetics of melanoma

Frontiers in Genetics

Volumn 3, Issue JAN, 2013, Pages

  Wangari Talbot, Janet ^a   Chen, Suzie ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Braf; Grm3; Mapk; Melanoma; Pi3k akt; Prex2; Rac1

Indexed keywords

EID: 84876183996     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00330     Document Type: Review

References (279)

1. Ackermann, J., Frutschi, M., Kaloulis, K., Mckee, T., Trumpp, A., and Beermann, F. (2005). Metastasiz-ing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65,4005-4011.
2. Albino, A. P., Nanus, D. M., Mentle, I. R., Cordon-Cardo, C., Mcnutt, N. S., Bressler, J., etal. (1989). Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 4,1363-1374.
3. Alessi, D. R., Andjelkovic, M., Caud-well, B., Cron, P., Morrice, N., Cohen, P., etal. (1996). Mechanism of activation of protein kinase B by insulin andIGF-1. EMBOJ. 15,6541-6551.
4. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., etal. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7,261-269.
5. Amaravadi, R. K., Schuchter, L. M., McDermott, D. F., Kramer, A., Giles, L., Gramlich, K., etal. (2009). Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metas-tases. Clin. Cancer Res. 15, 7711-7718.
6. American Cancer Society. (2012). Melanoma Skin Cancer. Available at: http://www.cancer.org/Cancer/Skin Cancer-Melanoma/DetailedGuide/ melanoma-skin-cancer-key-statistics (accessed September 24, 2012).
7. Anforth, R. M., Blumetti, T. C., Kef-ford, R. F., Sharma, R., Scolyer, R. A., Kossard, S., etal. (2012). Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br. J. Derma-tol. 167, 1153-1160.
8. Arboleda, M. J., Lyons, J. F., Kab-binavar, F. F., Bray, M. R., Snow, B. E., Ayala, R., etal. (2003). Overexpres-sion of AKT2/protein kinase Bbeta leads to up-regulation of beta1 inte-grins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63, 196-206.
9. Armstrong, B. K., and Kricker, A. (2001). The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B63,8-18.
10. Ascierto, P. A., Simeone, E., Giannarelli, D., Grimaldi, A. M., Romano, A., and Mozzillo, N. (2012). Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J. Transl Med. 10, 107.
11. Augustine, C. K., Toshimitsu, H., Jung, S. H., Zipfel, P. A., Yoo, J. S., Yoshi-moto, Y., etal. (2010). Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol. Cancer Ther. 9, 2090-2101.
12. Babu, G. J., Lalli, M. J., Sussman, M. A., Sadoshima, J., and Periasamy, M. (2000). Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy. J. Mol. Cell. Cardiol. 32, 1447-1457.
13. Bain, J., Mclauchlan, H., Elliott, M., and Cohen, P. (2003). The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204.
14. Baines, A. T., Xu, D., and Der, C. J. (2011). Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 3, 1787- 1808.
15. Ball, N. J., Yohn, J. J., Morelli, J. G., Nor-ris, D. A., Golitz, L. E., and Hoeffler, J. P. (1994). Ras mutations in human melanoma: a marker of malignant progression. J. Invest. Dermatol. 102, 285-290.
16. Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., and Chin, L. (2001). Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol. Cell. Biol. 21,2144-2153.
17. Bastian, B. C., Leboit, P. E., Hamm, H., Brocker, E. B., and Pinkel, D. (1998). Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 58,2170-2175.
18. Bastian, B. C., Leboit, P. E., and Pinkel, D. (2000). Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopatholog-ical features. Am. J. Pathol. 157, 967-972.
19. Becker, T. M., Rizos, H., Kefford, R. E, and Mann, G. J. (2001). Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding. Clin. Cancer Res. 7, 3282-3288.
20. Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., et al. (1995). Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280-285.
21. Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Pro-topopov, A., etal. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
22. Berwick, M., Orlow, I., Hummer, A. J., Armstrong, B. K., Kricker, A., Marrett, L. D., etal. (2006). The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol. Biomarkers Prev. 15, 1520-1525.
23. Bishop, D. T., Demenais, F., Goldstein, A. M., Bergman, W., Bishop, J. N., Bressac-De Paillerets, B., et al. (2002). Geographical variation in the pen-etrance of CDKN2A mutations for melanoma. J. Natl. Cancer Inst. 94, 894-903.
24. Boers-Sonderen, M. J., Desar, I. M., Blokx, W., Timmer-Bonte, J. N., and Van Herpen, C. M. (2012). A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). Anticancer. Drugs 23,761-764.
25. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., etal. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599.
26. Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C. N., Sloss, C. M., etal. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213-5219.
27. Bos, J. L. (1989). ras oncogenes in human cancer: a review. Cancer Res. 49,4682-4689.
28. Bradl, M., Klein-Szanto, A., Porter, S., and Mintz, B. (1991). Malignant melanoma in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 88, 164-168.
29. Britten, C. D., Rowinsky, E. K., Soignet, S., Patnaik, A., Yao, S. L., Deutsch, P., etal. (2001). A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin. Cancer Res. 7, 3894-3903.
30. Brognard, J., Clark, A. S., Ni, Y., and Dennis, P. A. (2001). Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61, 3986-3997.
31. Brose, M. S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., et al. (2002). BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997-7000.
32. Cales, C., Hancock, J. F., Marshall, C. J., and Hall, A. (1988). The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product. Nature 332, 548-551.
33. Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G.,Wilhelm, S. M., et al. (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 98, 326-334.
34. Carracedo, A.,andPandolfi,P.P. (2008). The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27, 5527-5541.
35. Catalanotti, F., and Solit, D. B. (2012). Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas? Clin. Cancer Res. 18,2420-2422.
36. Chan, T. O., Rodeck, U., Chan, A. M., Kimmelman, A. C., Rittenhouse, S. E., Panayotou, G., etal. (2002). Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1, 181-191.
37. Chang, Y. S., Adnane, J., Trail, P. A., Levy, J., Henderson, A., Xue, D., et al. (2007). Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol. 59,561-574.
38. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., etal. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364,2507-2516.
39. Chen, L., Agrawal, S., Zhou, W., Zhang, R., and Chen, J. (1998). Synergis-tic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. U.S.A. 95, 195-200.
40. Cheng, J. Q., Godwin, A. K., Bella-cosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., etal. (1992). AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. U.S.A. 89, 9267-9271.
41. Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., etal. (1996). Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. U.S.A. 93, 3636-3641.
42. Cheung, M., Sharma, A., Madhuna-pantula, S. V., and Robertson, G. P. (2008). Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 68,3429-3439.
43. Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., etal. (1997). Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11, 2822-2834.
44. Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., etal. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature 400,468-472.
45. Cockburn, M., Swetter, S. M., Peng, D., Keegan, T. H., Deapen, D., and Clarke, C. A. (2008). Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J. Am. Acad. Dermatol. 59, 1081-1085.
46. Colombo, S., Peri, F., Tisi, R., Nicotra, F., and Martegani, E. (2004). Design and characterization of a new class of inhibitors of ras activation. Ann. N. Y.Acad. Sci. 1030,52-61.
47. Comin-Anduix, B., Chodon, T., Saze-gar, H., Matsunaga, D., Mock, S., Jalil, J., etal. (2010). The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin. Cancer Res. 16, 6040-6048.
48. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789.
49. Cully, M., You, H., Levine, A. J., and Mak, T. W (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192.
50. Currie, R. A., Macleod, B. M., and Downes, C. P. (1997). The lipid transfer activity of phosphatidyli-nositol transfer protein is sufficient to account for enhanced phospholi-pase C activity in turkey erythrocyte ghosts. Curr. Biol. 7, 184-190.
51. Cust, A. E., Harland, M., Makalic, E., Schmidt, D., Dowty, J. G., Aitken, J. F., etal. (2011). Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK. J. Med. Genet. 48,266-272.
52. Dahlman, K. B., Xia, J., Hutchinson, K., Ng, C., Hucks, D., Jia, P., et al. (2012). BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2, 791-797.
53. Dankort, D., Curley D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky, W. E. Jr., etal. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
54. Datta, K., Franke, T. F., Chan, T. O., Makris, A., Yang, S. I., Kaplan, D. R., etal. (1995). AH/PH domain-mediated interaction between Akt molecules and its potential role in Akt regulation. Mol. Cell. Biol. 15, 2304-2310.
55. Davies, B. R., Logie, A., Mckay, J. S., Martin, P., Steele, S., Jenkins, R., et al. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, phar-macokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6, 2209-2219.
56. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., etal. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
57. Daya-Grosjean, L., and Sarasin, A. (2005). The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat. Res. 571,43-56.
58. Demunter, A., Ahmadian, M. R., Lib-brecht, L., Stas, M., Baens, M., Schef-fzek, K., etal. (2001). A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res. 61,4916-4922.
59. DePinho, R. A. (1998). Transcriptional repression. The cancer-chromatin connection. Nature 391, 533, 535-536.
60. Der, C. J., Finkel, T., and Cooper, G. M. (1986). Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 44, 167-176.
61. Dhawan, P., Singh, A. B., Ellis, D. L., and Richmond, A. (2002). Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 62, 7335- 7342.
62. Dhomen, N., Reis-Filho, J. S., Da Rocha Dias, S., Hayward, R., Savage, K., Del-mas, V., etal. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294-303.
63. Dinsmore, C. J., and Bell, I. M. (2003). Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: substrate-based design, conformational constraint and biological activity. Curr. Top. Med. Chem. 3, 1075-1093.
64. Domchek, S. M., Auger, K. R., Chat-terjee, S., Burke, T. R. Jr., and Shoelson, S. E. (1992). Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phospho-nopeptide. Biochemistry 31, 9865-9870.
65. Dong, L. Q., Zhang, R. B., Langlais, P., He, H., Clark, M., Zhu, L., etal. (1999). Primary structure, tissue distribution, and expression of mouse phosphoinositide-dependent protein kinase-1, a protein kinase that phosphorylates and activates protein kinase Czeta. J. Biol. Chem. 274, 8117-8122.
66. Downward, J. (1996). Control of ras activation. Cancer Surv. 27, 87-100.
67. Dumaz, N., Hayward, R., Martin, J., Ogilvie, L., Hedley, D., Curtin, J. A., etal. (2006). In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66, 9483- 9491.
68. Edinger, A. L., and Thompson, C. B. (2002). Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 2276-2288.
69. Egberts, F., Gutzmer, R., Ugurel, S., Becker, J. C., Trefzer, U., Degen, A., etal. (2011). Sorafenib and pegy-lated interferon-alpha2b in advanced metastatic melanoma: a multicenter phaseII DeCOG trial. Ann. Oncol. 22, 1667-1674.
70. Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., etal. (2006). Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581-586.
71. End, D. W., Smets, G., Todd, A. V., Applegate, T. L., Fuery, C. J., Angibaud, P., etal. (2001). Characterization of the antitumor effects of the selective farnesyl protein trans-ferase inhibitor R1 15777 in vivo and in vitro. Cancer Res. 61, 131-137.
72. Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upad-hyay, R., etal. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14,1351-1356.
73. Ernst, D. S., Eisenhauer, E., Wainman, N., Davis, M., Lohmann, R., Baetz, T., et al. (2005). Phase II study of perifo-sine in previously untreated patients with metastatic melanoma. Invest. New Drugs 23, 569-575.
74. Escudier, B., Eisen, T., Stadler, W M., Szczylik, C., Oudard, S., Staehler, M., etal. (2009). Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27,3312-3318.
75. Eskandarpour, M., Kiaii, S., Zhu, C., Castro, J., Sakko, A. J., and Hansson, J. (2005). Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int. I Cancer 115,65-73.
76. Estep, A. L., Palmer, C., McCormick, F., and Rauen, K. A. (2007). Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS ONE 2:e1279. doi: 10.1371/journal.pone.0001279
77. Faivre, S., Kroemer, G., and Raymond, E. (2006). Current development of mTOR inhibitors as anti-cancer agents. Nat. Rev. Drug Discov. 5,671-688.
78. Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., Demarini, D. J., etal. (2012a). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13, 782-789.
79. Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., etal. (2012b). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
80. Fasolo, A., and Sessa, C. (2008). mTOR inhibitors in the treatment of cancer. Expert Opin. Investig. Drugs 17, 1717-1734.
81. Fine, B., Hodakoski, C., Koujak, S., Su, T., Saal, L. H., Maurer, M., et al. (2009). Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 325, 1261-1265.
82. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., Mcarthur, G. A., Sos-man, J. A., etal. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363,809-819.
83. Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., etal. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl J. Med. 367, 107-114.
84. Forino, M., Jung, D., Easton, J. B., Houghton, P. J., and Pellecchia, M. (2005). Virtual docking approaches to protein kinase B inhibition. J. Med. Chem. 48,2278-2281.
85. Fountain, J. W., Karayiorgou, M., Ernstoff, M. S., Kirkwood, J. M., Vlock, D. R., Titus-Ernstoff, L., etal. (1992). Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. Natl. Acad. Sci. U.S.A. 89, 10557-10561.
86. Franke, T. F. (2008). PI3K/Akt: getting it right matters. Oncogene 27, 6473-6488.
87. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., et al. (1995). The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81,727-736.
88. Gajewski, T. F., Niedzwiecki, D., Johnson, J., Linette, G., Bucher, C., Blaskovich, M., etal. (2006). Phase II study of the farnesyltrans-ferase inhibitor R115777 in advanced melanoma: CALGB 500104. J. Clin. Oncol. 24(Suppl.), Abstr. 8014.
89. Garcia-Echeverria, C., and Sellers, W. R. (2008). Drug discoveryapproaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511-5526.
90. Garnett, M. J., and Marais, R. (2004). Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313-319.
91. Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., etal. (2012). MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med. doi: 10.1038/nm.2863 [Epub ahead of print].
92. Gilmartin, A. G., Bleam, M. R., Groy, A., Moss, K. G., Minthorn, E. A., Kulkarni, S. G., etal. (2011). GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacoki-netic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17,989-1000.
93. Goel, V. K., Lazar, A. J., Warneke, C. L., Redston, M. S., and Haluska, F. G. (2006). Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 126, 154-160.
94. Goldstein, A. M., Chan, M., Harland, M., Hayward, N. K., Demenais, F., Bishop, D. T., etal. (2007). Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J. Med. Genet. 44, 99-106.
95. Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445,851-857.
96. Gray-Schopfer, V. C., Cheong, S. C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z. A., etal. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496-505.
97. Greenblatt, M. S., Bennett, W. P., Holl-stein, M., and Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878.
98. Greene, M. H., and Fraumeni, J. F. Jr. (1979). The Hereditary Variant of Malignant Melanoma. New York: Grune and Stratton.
99. Greger, J. G., Eastman, S. D., Zhang, V., Bleam, M. R., Hughes, A. M., Smitheman, K. N., etal. (2012). Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11,909-920.
100. Gunning, W. T., Kramer, P. M., Lubet, R. A., Steele, V. E., End, D. W., Wouters, W., etal. (2003). Chemopreven-tion of benzo(a)pyrene-inducedlung tumors in mice by the farnesyltrans-ferase inhibitor R1 15777. Clin. Cancer Res. 9,1927-1930.
101. Gysin, S., Salt, M., Young, A., and McCormick, F. (2011). Therapeutic strategies for targeting ras proteins. Genes Cancer 2, 359-372.
102. Hacker, E., Irwin, N., Muller, H. K., Powell, M. B., Kay, G., Hayward, N., etal. (2005). Neonatal ultraviolet radiation exposure is critical for malignant melanoma induction in pigmented Tpras transgenic mice. J. Invest. Dermatol. 125, 1074-1077.
103. Hainsworth, J. D., Infante, J. R., Spigel, D. R., Peyton, J. D., Thompson, D. S., Lane, C. M., etal. (2010). Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 116,4122-4129.
104. Harland, M., Goldstein, A. M., Kukalizch, K., Taylor, C., Hogg, D., Puig, S., etal. (2008). A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur. J. Cancer 44, 1269-1274.
105. Haslam, R. J., Koide, H. B., and Hemmings, B. A. (1993). Pleck-strin domain homology. Nature 363, 309-310.
106. Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., etal. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435.
107. Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., etal. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
108. Hay, N., and Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945.
109. Heidorn, S. J., Milagre, C., Whit-taker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., etal. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221.
110. Herrmann, C., Horn, G., Spaargaren, M.,andWittinghofer,A. (1996). Differential interaction of the ras family GTP-binding proteins H-Ras, Rap 1 A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor. J. Biol Chem. 271, 6794-6800.
111. Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., etal. (2010). MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeu-tic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 9, 1956-1967.
112. Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theuril-lat, J. P., etal. (2012). A landscape of driver mutations in melanoma. Cell 150,251-263.
113. Hoeflich, K. P., Herter, S., Tien, J., Wong, L., Berry, L., Chan, J., etal. (2009). Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E muta-tional status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 69,3042-3051.
114. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., etal. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22, 3551-3555.
115. Houben, R., Becker, J. C., Kappel, A., Terheyden, P., Brocker, E. B., Goetz, R., etal. (2004). Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog. 3, 6.
116. Hupp, T. R., Meek, D. W., Midgley, C. A., and Lane, D. P. (1992). Regulation of the specific DNA binding function ofp53. Cell 71, 875-886.
117. Hupp, T. R., Sparks, A., and Lane, D. P. (1995). Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83, 237-245.
118. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., Sheahan, M. D., etal. (1994). Germline p16 mutations in familial melanoma. Nat. Genet. 8, 15-21.
119. Ikehara, N., Semba, S., Sakashita, M., Aoyama, N., Kasuga, M., and Yokozaki, H. (2005). BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int. J. Cancer 115, 943-950.
120. Ikenoue, T., Hikiba, Y., Kanai, F., Aragaki, J., Tanaka, Y., Imamura, J., etal. (2004). Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res. 64, 3428-3435.
121. Isosaki, M., Nakayama, H., Kyotani, Y., Zhao, J., Tomita, S., Satoh, H.,etal. (2011). Prevention of the wortmannin-induced inhibition of phosphoinositide 3-kinase by sulfhydryl reducing agents. Pharmacol Rep. 63, 733-739.
122. Jafari, M., Papp, T., Kirchner, S., Diener, U., Henschler, D., Burg, G.,etal. (1995). Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J. Cancer Res. Clin. Oncol. 121,23-30.
123. James, G., Goldstein, J. L., and Brown, M. S. (1996). Resistance of K-RasBV12 proteins to farnesyltrans-ferase inhibitors in Rat1 cells. Proc. Natl. Acad. Sci. U.S.A. 93, 4454-4458.
124. Jemal, A., Devesa, S. S., Hartge, P., and Tucker, M. A. (2001). Recent trends in cutaneous melanoma incidence among whites in the United States. J. Natl. Cancer Inst. 93, 678-683.
125. Jenkins, N. C., Liu, T., Cassidy, P., Leach-man, S. A., Boucher, K. M., Goodson, A. G.,etal. (2011). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene 30, 265-274.
126. Jiang, B. H., and Liu, L. Z. (2008). PI3K/PTEN signaling in tumorigen-esis and angiogenesis. Biochim. Bio-phys.Acta 1784, 150-158.
127. Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A.,etal. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
128. Johnson, G. L., and Lapadat, R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298,1911-1912.
129. Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N., Ding, W.,etal. (1994). Analysis of the p 16 gene (CDKN2) as acandidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8, 22-26.
130. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. (1998). Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. U.S.A. 95, 8292-8297.
131. Karst, A. M., Dai, D. L., Cheng, J. Q., and Li, G. (2006). Role of p53 up-regulated modulator of apoptosisand phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res. 66, 9221-9226.
132. Kim, D. H., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K. V., Erdjument-Bromage, H., et al. (2003). GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell. 11, 895-904.
133. Kim, M. S., Jeong, E. G., Ahn, C. H., Kim, S. S., Lee, S. H., and Yoo, N. J. (2008). Frameshift mutation of UVRAG, an autophagy-related gene, in gastric carcinomas with microsatellite instability. Hum. Pathol. 39, 1059-1063.
134. King, A. J., Patrick, D. R., Batorsky, R. S., Ho, M. L., Do, H. T., Zhang, S. Y., et al. (2006). Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66, 11100-11105.
135. Knight, Z. A., and Shokat, K. M. (2007). Chemically targeting the PI3K family. Biochem. Soc. Trans. 35, 245-249.
136. Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana, P., Downward, J., and Parker, P. J. (1994). The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol. 4, 798-806.
137. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., Desolms, S. J.,etal. (1995). Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1, 792-797.
138. Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., Mccusker, J. P.,etal. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
139. Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., and Berns, A. (2001). Loss of p 16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413, 83-86.
140. Kumar, R., Angelini, S., Czene, K., Sauroja, I., Hahka-Kemppinen, M., Pyrhonen, S.,etal. (2003). BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 9, 3362- 3368.
141. Kumar, R., Smeds, J., Berggren, P., Straume, O., Rozell, B. L., Akslen, L. A.,etal. (2001). A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int. J. Cancer 95, 388-393.
142. Lai, F., Jin, L., Gallagher, S., Mijatov, B., Zhang, X. D., and Hersey, P. (2012). Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors. Adv. Pharmacol. 65, 27-43.
143. Lawlor, M. A., and Alessi, D. R. (2001). PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?J. Cell Sci. 114,2903-2910.
144. Lazovich, D., Vogel, R. I., Berwick, M., Weinstock, M. A., Anderson, K. E., and Warshaw, E. M. (2010). Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol. Biomarkers Prev. 19, 1557-1568.
145. Lee, H.J., Wall, B. A., Wangari-Talbot, J., Shin, S. S., Rosenberg, S., Chan, J. L.,etal. (2011). Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin. Cancer Res. 17,7080-7092.
146. Lee, J. T., Li, L., Brafford, P. A., Van Den Eijnden, M., Halloran, M. B., Sproesser, K., etal. (2010). PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res. 23, 820-827.
147. Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., Mclellan, M. D., Chen, K.,etal. (2008). DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72.
148. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I.,etal. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
149. Li, L., and Ross, A. H. (2007). Why is PTEN an important tumor suppressor?J. Cell. Biochem. 102,1368-1374.
150. Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K.,etal. (2002). PKB/Akt phospho-rylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8,1153-1160.
151. Lierman, E., Folens, C., Stover, E. H., Mentens, N., Van Miegroet, H., Scheers, W.,etal. (2006). Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 108, 1374-1376.
152. Link, D. C., Schuettpelz, L. G., Shen, D., Wang, J., Walter, M. J., Kulka-rni, S.,etal. (2011). Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 305, 1568-1576.
153. Liu, L., Dilworth, D., Gao, L., Monzon, J., Summers, A., Lassam, N.,etal. (1999). Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Nat. Genet. 21,128-132.
154. Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H. G., Brucker, M. J., Buser, C. A.,etal. (2001). Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in pre-clinical models. Cancer Res. 61,8758- 8768.
155. Lopez-Bergami, P., Huang, C., Goydos, J. S., Yip, D., Bar-Eli, M., Herlyn, M.,etal. (2007). Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11,447-460.
156. Lovly, C. M., Dahlman, K. B., Fohn, L. E., Su, Z., Dias-Santagata, D., Hicks, D. J.,etal. (2012). Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE 7:e35309. doi: 10.1371/journal.pone.0035309
157. Lowy, D. R., and Willumsen, B. M. (1993). Function and regulation of ras. Annu. Rev. Biochem. 62, 851-891.
158. Luu, Y., and Li, G. (2003). The p53-stabilizing compound, CP-31398, does not enhance chemosensitivity in human melanoma cells. Anticancer. Res. 23, 99-105.
159. Lyons, J. F., Wilhelm, S., Hibner, B., and Bollag, G. (2001). Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer8, 219-225.
160. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., and Pandolfi, P. P. (2005). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193.
161. Madhunapantula, S. V., Sharma, A., and Robertson, G. P. (2007). PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 67, 3626-3636.
162. Manning, B. D., and Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
163. Mao, J. H., To, M. D., Perez-Losada, J., Wu, D., Del Rosario, R., and Balmain, A. (2004). Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes Dev. 18,1800-1805.
164. Marais, R., Light, Y., Paterson, H. F., and Marshall, C. J. (1995). Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBOJ. 14, 3136-3145.
165. Margolin, K. A., Moon, J., Flaherty, L. E., Lao, C. D., Akerley, W. L. III, Othus, M.,etal. (2012). Randomized phase II trial of sorafenib withtemsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin. Cancer Res. 18,1129-1137.
166. Marine, J. C., and Jochemsen, A. G. (2005). Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun. 331, 750-760.
167. Marks, J. L., Gong, Y., Chitale, D., Golas, B., Mclellan, M. D., Kasai, Y.,etal. (2008). Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung ade-nocarcinoma. Cancer Res. 68, 5524- 5528.
168. McDermott, D. F., Sosman, J. A., Gonzalez, R., Hodi, F. S., Linette, G. P., Richards, J.,etal. (2008). Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.J. Clin. Oncol. 26,2178-2185.
169. Mehnert, J. M., Semlani, N., Wen, Y., Tan, A. R., Moss, R. A., Adams, S.,etal. (2012). A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma.J. Clin. Oncol. 30(Suppl.), Abstr. TPS3112.
170. Mehnert, J. M., Wen, Y., Lee, J. H., Dudek, L., Pruski-Clark, L., Shih, W.,etal. (2011). A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor (GRM1) signaling, in advanced melanoma. J. Clin. Oncol. 29(Suppl.), Abstr. 8557.
171. Meier, F., Guenova, E., Clasen, S., Eigentler, T., Forschner, A., Leiter, U.,etal. (2009). Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. J. Am. Acad. Dermatol. 60, 863-868.
172. Michaloglou, C., Vredeveld, L. C.,Soen-gas, M. S., Denoyelle, C., Kuil-man, T., Van Der Horst, C. M., etal. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
173. Milagre, C., Dhomen, N., Geyer, F. C., Hayward, R., Lambros, M., Reis-Filho, J. S.,etal. (2010). A mouse model of melanoma driven by onco-genic KRAS. Cancer Res. 70, 5549-5557.
174. Mirza, A. M., Kohn, A. D., Roth, R. A., and McMahon, M. (2000). Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Cell Growth Differ. 11,279-292.
175. Monahan, K. B., Rozenberg, G. I., Krish-namurthy, J., Johnson, S. M., Liu, W., Bradford, M. K.,etal. (2010). Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene 29, 5809-5817.
176. Monje, P., Hernandez-Losa, J., Lyons, R. J., Castellone, M. D., and Gutkind, J. S. (2005). Regulation of the tran-scriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J. Biol. Chem. 280, 35081-35084.
177. Murugan, A. K., Dong, J., Xie, J., and Xing, M. (2009). MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle 8, 2122-2124.
178. Naidu, S., Vijayan, V., Santoso, S., Kietzmann, T., and Immenschuh, S. (2009). Inhibition and genetic deficiency of p38 MAPK up-regulates heme oxygenase-1 gene expression via Nrf2. J. Immunol. 182, 7048-7057.
179. Nakatani, K., Sakaue, H., Thompson, D. A., Weigel, R. J., and Roth, R. A. (1999). Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory ser-ine phosphorylation site. Biochem. Biophys. Res. Commun. 257,906-910.
180. Namkoong, J., Shin, S. S., Lee, H. J., Marin, Y. E., Wall, B. A., Goydos, J. S., et al. (2007). Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res. 67, 2298-2305.
181. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H.,etal. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
182. Nikolaev, S. I., Rimoldi, D., Iseli, C., Valsesia, A., Robyr, D., Gehrig, C., et al. (2012). Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44, 133-139.
183. Nogueira, C., Kim, K. H., Sung, H., Paraiso, K. H., Dannenberg, J. H., Bosenberg, M.,etal. (2010). Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29, 6222-6232.
184. Oberholzer, P. A., Kee, D., Dziunycz, P., Sucker, A., Kamsukom, N., Jones, R.,etal. (2012). RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30,316-321.
185. Ott, P. A., Hamilton, A., Min, C., Safarzadeh-Amiri, S., Goldberg, L., Yoon, J.,etal. (2010). A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS ONE 5:e15588. doi: 10.1371/journal.pone.0015588
186. Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H.,etal. (2000). Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103, 931-943.
187. Parmiter, A. H., and Nowell, P. C. (1988). The cytogenetics of human malignant melanoma and premalig-nant lesions. Cancer Treat. Res. 43, 47-61.
188. Patton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey, R. D.,etal. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15,249-254.
189. Pawson, T. (2004). Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell 116, 191-203.
190. Peri, F., Airoldi, C., Colombo, S., Marte-gani, E., Van Neuren, A. S., Stein, M.,etal. (2005). Design, synthesis and biological evaluation of sugar-derived Ras inhibitors. Chembiochem 6, 1839-1848.
191. Pfeifer, G. P., You, Y. H., and Besara-tinia, A. (2005). Mutations induced by ultraviolet light. Mutat. Res. 571, 19-31.
192. Pleasance, E. D., Cheetham, R. K., Stephens, P. J., Mcbride, D. J., Humphray, S. J., Greenman, C. D.,etal. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196.
193. Pollock, P., Harper, U., Hansen, K., Yudt, L., Stark, M., Robbins, C.,etal. (2003a). High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19-20.
194. Pollock, P. M., Cohen-Solal, K., Sood, R., Namkoong, J., Martino, J. J., Koganti, A.,etal. (2003b). Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat. Genet. 34, 108-112.
195. Pollock, P. M., Walker, G. J., Glendening, J. M., Que Noy, T., Bloch, N. C., Fountain, J. W., et al. (2002). PTEN inacti-vation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res. 12,565-575.
196. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L.,etal. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition ofp53. Cell 92, 713-723.
197. Poulikakos, P. I., Persaud, Y., Janakira-man, M., Kong, X., Ng, C., Moriceau, G.,etal. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390.
198. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., and Rosen, N. (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430.
199. Prickett, T. D., Wei, X., Cardenas-Navia, I., Teer, J. K., Lin, J. C., Walia, V.,etal. (2011). Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat. Genet. 43, 1119-1126.
200. Puente, X. S., Pinyol, M., Que-sada, V., Conde, L., Ordonez, G. R., Villamor, N.,etal. (2011). Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105.
201. Purdue, M. P., Freeman, L. E., Anderson, W E, and Tucker, M. A. (2008). Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J. Invest. Dermatol. 128, 2905-2908.
202. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. (1995). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000.
203. Rapp, U. R., Gotz, R., and Albert, S. (2006). BuCy RAFs drive cells into MEK addiction. Cancer Cell 9, 9-12.
204. Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V B., Lansing, T. J.,etal. (2008). Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 68, 2366-2374.
205. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J.,etal. (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370, 527-532.
206. Roskoski, R. Jr. (2012). MEK1/2 dual-specificity protein kinases: structure and regulation. Biochem. Biophys. Res. Commun. 417, 5-10.
207. Rubinfeld, H., and Seger, R. (2004). The ERK cascade as a prototype of MAPK signaling pathways. Methods Mol. Biol. 250, 1-28.
208. Rubinstein, J. C., Sznol, M., Pavlick, A. C., Ariyan, S., Cheng, E., Bacchioc-chi, A.,etal. (2010). Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J. Transl. Med. 8, 67.
209. Salmena, L., Carracedo, A., and Pandolfi, P. P. (2008). Tenets of PTEN tumor suppression. Cell 133, 403-414.
210. Samuels, Y., Wang, Z., Bardelli, A., Sil-liman, N., Ptak, J., Szabo, S.,etal. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554.
211. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
212. Sasaki, H., Hikosaka, Y., Kawano, O., Moriyama, S., Yano, M., and Fujii, Y. (2010). MEK1 and AKT2 mutations in Japanese lung cancer. J. Thorac. Oncol. 5, 597-600.
213. Scheffzek, K., Ahmadian, M. R., Kab-sch, W., Wiesmuller, L., Lautwein, A., Schmitz, F.,etal. (1997). The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277, 333-338.
214. Sebti, S. M., and Hamilton, A. D. (2000). Farnesyltransferase and geranylger-anyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19, 6584-6593.
215. Serrano, M., Hannon, G. J., and Beach, D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707.
216. Shao, Y., and Aplin, A. E. (2010). Akt3-mediated resistance to apop-tosis in B-RAF-targeted melanoma cells. Cancer Res. 70, 6670-6681.
217. Sharma, A., Sharma, A. K., Madhu-napantula, S. V., Desai, D., Huh, S. J., Mosca, P.,etal. (2009). Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin. Cancer Res. 15, 1674-1685.
218. Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., and Robertson, G. P. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65, 2412-2421.
219. Sharma, S., Kemeny, N., Kelsen, D. P., Ilson, D., O'Reilly, E., Zaknoen, S.,etal. (2002). A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann. Oncol. 13, 1067-1071.
220. Sharpless, E., and Chin, L. (2003). The INK4a/ARF locus and melanoma. Oncogene 22, 3092-3098.
221. Sharpless, N. E., Bardeesy, N., Lee, K. H., Carrasco, D., Castrillon, D. H., Aguirre, A. J.,etal. (2001). Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413, 86-91.
222. Sherr, C. J., and Roberts, J. M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13,1501-1512.
223. Shi, H., Moriceau, G., Kong, X., Lee, M. K., Lee, H., Koya, R. C.,etal. (2012). Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Com-mun. 3, 724.
224. Shin, I., Yakes, E M., Rojo, F., Shin, N. Y., Bakin, A. V., Baselga, J.,etal. (2002). PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) atthreonine 157andmod-ulation of its cellular localization. Nat.Med. 8, 1145-1152.
225. Shin, S. S., Wall, B. A., Goydos, J. S., and Chen, S. (2010). AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell Melanoma Res. 23, 103-111.
226. Shukla, V. K., Hughes, D. C., Hughes, L. E., McCormick, F., and Padua, R. A. (1989). ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res. 5, 121-127.
227. Si, L., Xu, X., Kong, Y., Flaherty, K. T., Chi, Z., Cui, C.,etal. (2012). Major response to everolimus in melanoma with acquired imatinib resistance. J. Clin. Oncol. 30, e37-e40.
228. Sinnberg, T., Lasithiotakis, K., Niess-ner, H., Schittek, B., Flaherty, K. T., Kulms, D.,etal. (2009). Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J. Invest. Dermatol. 129, 1500-1515.
229. Sood, A. K., Saxena, R., Groth, J., Desouki, M. M., Cheewakri-angkrai, C., Rodabaugh, K. J.,etal. (2007). Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum. Pathol. 38, 1628-1638.
230. Staal, S. P. (1987). Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 84, 5034-5037.
231. Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W.,etal. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010.
232. Stambolic, V., Suzuki, A., De La Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., etal. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95,29-39.
233. Stassi, G., Garofalo, M., Zerilli, M., Ricci-Vitiani, L., Zanca, C., Todaro, M.,etal. (2005). PED mediates AKT-dependent chemoresistance in human breast cancer cells. Cancer Res. 65, 6668-6675.
234. Stewart, A. L., Mhashilkar, A. M., Yang, X. H., Ekmekcioglu, S., Saito, Y., Sieger, K.,etal. (2002). PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol. Med. 8,451-461.
235. Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J.,etal. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504.
236. Su, F., Viros, A., Milagre, C., Trun-zer, K., Bollag, G., Spleiss, O.,etal. (2012). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215.
237. Suzuki, A., De La Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., Del BarcoBarrantes,I.,etal. (1998).High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169-1178.
238. Taveras, A. G., Remiszewski, S. W., Doll, R. J., Cesarz, D., Huang, E. C., Kirschmeier, P.,etal. (1997). Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg. Med. Chem. 5, 125-133.
239. Toker, A., and Newton, A. C. (2000). Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J. Biol. Chem. 275, 8271-8274.
240. Trahey, M., and McCormick, F. (1987). A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238, 542-545.
241. Trahey, M., Milley, R. J., Cole, G. E., Innis, M., Paterson, H., Marshall, C. J.,etal. (1987). Biochemical and biological properties of the human N-ras p21 protein. Mol. Cell. Biol. 7, 541-544.
242. Tran, M. A., Gowda, R., Sharma, A., Park, E. J., Adair, J., Kester, M.,etal. (2008). Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 68,7638-7649.
243. Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S.,etal. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U.S.A. 105, 3041-3046.
244. Tsao, H., Goel, V., Wu, H., Yang, G., and Haluska, F. G. (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inac-tivation in melanoma. J. Invest. Dermatol. 122,337-341.
245. Tsao, H., Zhang, X., Fowlkes, K., and Haluska, F. G. (2000). Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 60,1800-1804.
246. Turajlic, S., Furney, S. J., Lambros, M. B., Mitsopoulos, C., Kozarewa, I., Geyer, F. C.,etal. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 22,196-207.
247. van Elsas, A., Zerp, S. F., Van Der Flier, S., Kruse, K. M., Aarnoudse, C.,Hayward,N.K.,etal. (1996). Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol. 149, 883-893.
248. Vassilev, L. T. (2004). Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3,419-421.
249. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z.,etal. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848.
250. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. (1994). A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241-5248.
251. Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pocha-nard, P.,etal. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096.
252. Wan, P. T., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V M.,etal. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116,855-867.
253. Wangari-Talbot, J., Wall, B. A., Goydos, J. S., and Chen, S. (2012). Functional effects of GRM1 suppression in human melanoma cells. Mol. Cancer Res. 10,1440-1450.
254. Weber, C. K., Slupsky, J. R., Kalmes, H. A., and Rapp, U. R. (2001). Active Ras induces heterodimerization of cRaf andBRaf. Cancer Res. 61,3595-3598.
255. Weber, J. S., Hamid, O., Chasalow, S. D., Wu, D. Y., Parker, S. M., Galbraith, S.,etal. (2012). Ipili-mumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J. Immunother. 35, 89-97.
256. Wei, X., Walia, V., Lin, J. C., Teer, J. K., Prickett, T. D., Gartner, J.,etal. (2011).Exomesequencingiden-tifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.
257. Welch, J. S., Westervelt, P., Ding, L., Larson, D. E., Klco, J. M., Kulka-rni, S.,etal. (2011). Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305, 1577-1584.
258. Wellbrock, C., Karasarides, M., and Marais, R. (2004a). The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875-885.
259. Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D.,etal. (2004b). V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342.
260. Whitwam, T., Vanbrocklin, M. W., Russo, M. E., Haak, P. T., Bilgili, D., Resau, J. H., et al. (2007). Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene 26,4563-4570.
261. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., Mcnabola, A., Rong, H.,etal. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109.
262. Wittinghofer, A., Scheffzek, K., and Ahmadian, M. R. (1997). The interaction of Ras with GTPase-activating proteins. FEBS Lett. 410, 63-67.
263. Wong, H., Belvin, M., Herter, S., Hoe-flich, K. P., Murray, L. J., Wong, L.,etal. (2009). Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyrid-ine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phospho-rylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J. Pharmacol. Exp. Ther. 329, 360-367.
264. Wu, H., Goel, V., and Haluska, F. G. (2003). PTEN signaling pathways in melanoma. Oncogene 22, 3113-3122.
265. Wymann, M. P., Bulgarelli-Leva, G., Zvelebil, M. J., Pirola, L., Van-haesebroeck, B., Waterfield, M. D.,etal. (1996). Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 16, 1722-1733.
266. Yadav, V., Zhang, X., Liu, J., Estrem, S., Li, S., Gong, X. Q., et al. (2012). Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J. Biol. Chem. 287, 28087-28098.
267. Yaguchi, S., Fukui, Y., Koshimizu, I., Yoshimi, H., Matsuno, T., Gouda, H.,etal. (2006). Antitumor activity of ZSTK474, a new phosphatidylinosi-tol 3-kinase inhibitor. J. Natl. Cancer Inst. 98, 545-556.
268. Yang, F. C., Merlino, G., and Chin, L. (2001). Genetic dissection of melanoma pathways in the mouse. Semin. Cancer Biol. 11,261-268.
269. Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R.,etal. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclini-calmelanomamodels. CancerRes. 70, 5518-5527.
270. Yin, Y., and Shen, W H. (2008). PTEN: a new guardian of the genome. Oncogene 27, 5443-5453.
271. Yip, D., Le, M. N., Chan, J. L., Lee, J. H., Mehnert, J. A., Yudd, A.,etal. (2009). A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin. Cancer Res. 15, 3896-3902.
272. Young, J., Barker, M. A., Simms, L. A., Walsh, M. D., Biden, K. G., Buchanan, D.,etal. (2005). Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin. Gastroenterol. Hepatol. 3, 254-263.
273. Young, K., Minchom, A., and Larkin, J. (2012). BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol. 8, 499-507.
274. Yuan, T. L., and Cantley, L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510.
275. Yuan, Z. Q., Feldman, R. I., Sussman, G. E., Coppola, D., Nicosia, S. V., and Cheng, J. Q. (2003). AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphoryla-tion of ASK1: implication of AKT2 in chemoresistance. J. Biol. Chem. 278, 23432-23440.
276. Yuen, S. T., Davies, H., Chan, T. L., Ho, J. W., Bignell, G. R., Cox, C.,etal. (2002). Similarity of the pheno-typic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. CancerRes. 62,6451-6455.
277. Zhang, Y., Xiong, Y., and Yarbrough, W G. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734.
278. Zhu, H., Reuhl, K., Zhang, X., Botha, R., Ryan, K., Wei, J.,etal. (1998). Development of heritable melanoma in transgenic mice. J. Invest. Dermatol. 110,247-252.
279. Zinda, M. J., Johnson, M. A., Paul, J. D., Horn, C., Konicek, B. W., Lu, Z. H.,etal. (2001). AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin. Cancer Res. 7, 2475-2479.